Food and Drug Administration import alerts on the following have been modified in the past week.
- processed human and animal foods
- raw agricultural products
- unapproved new drugs
- foods containing illegal and/or undeclared colors
- seafood products
- raw and cooked shrimp from India
- food products that appear to be misbranded
- food products containing sulfites
- surgeon’s and patient examination gloves
- medical instruments from Pakistan
- aquaculture seafood products
- fish/fishery products from foreign processors not in compliance with seafood HACCP
- firms refusing FDA foreign establishment inspection
[Click here for ST&R’s on-demand webinar on how to avoid costs and delays from FDA import alerts.]
Importers of FDA-regulated goods are responsible for ensuring that such imports are in compliance with FDA laws and regulations. Before shipping into the U.S., importers should be aware of whether or not their product is listed on an import alert.
Import alerts inform FDA field staff that the agency has enough evidence or other information to allow a product that appears to be in violation of FDA laws and regulations to be detained without physical examination at the time of entry. Import alerts may cover products from designated countries or areas (including from all foreign countries), manufacturers, or shippers.
Firms and/or products on the “red list” of an import alert are subject to DWPE, while firms and/or products on the “green list” are not because they have met the criteria for exclusion. Some import alerts include a “yellow list” of firms, products, and/or countries subject to intensified surveillance because the nature of the violations may warrant further field examinations of individual entries and/or additional analyses. In addition, depending on the specific import alert, shipments of products subject to DWPE may still be imported into the U.S. if the importer has demonstrated that the shipment is in compliance.
If a product is detained without physical examination the importer has the right to provide evidence to the FDA in an attempt to overcome the appearance of the violation. If no such evidence is submitted, or if the evidence provided is insufficient to overcome the appearance of the violation, the product will be subject to refusal of entry into the U.S.
Copyright © 2021 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.